首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献，搜索用时 812 毫秒
1.
Thirty-seven fluoroquinolone-resistant Escherichia coli strains from ruminants (according to Clinical and Laboratory Standards Institute guidelines) were screened by molecular methods for mutations in the quinolone resistance-determining region (QRDR) of the gyrA and parC genes and for the presence of the qnrA gene. One of the strains studied was an enterohemorrhagic E. coli (EHEC) strain potentially pathogenic for humans. Three E. coli strains resistant to enrofloxacin (minimal inhibitory concentration [MIC] = 2 microg/ml) but not to ciprofloxacin (MIC = 1 microg/ml) presented single mutations in the gyrA and parC genes, while 34 strains resistant to both fluoroquinolones presented double and single mutations in gyrA and parC, respectively (31 strains), or double mutations in gyrA and parC (3 strains). The EHEC strain presented a double amino acid substitution in the GyrA protein (Ser-83-->Leu and Asp-87-->Gly) and a double amino acid substitution in the ParC protein (Gly-78-->Cys and Ser-80-->Arg), one of which has not been previously described. The present study shows that most of the mutations in the QRDR of the gyrA and parC genes of fluoroquinolone-resistant E. coli strains from ruminants are the same as those seen in E. coli strains from other animal species and humans and that there are no differences in mutation patterns in the QRDR of E. coli strains from healthy ruminants and those with diarrhea. No strains carried qnrA, which indicates that this gene does not play an important role in the selection of fluoroquinolone-resistant E. coli strains from ruminants.  相似文献   

2.
Quinolone-resistant (QR) mutants of Mycoplasma bovirhinis strain PG43 (type strain) were generated by stepwise selection in increasing concentrations of enrofloxacin (ENR). An alteration was found in the quinolone resistance-determining region (QRDR) of the parC gene coding for the ParC subunit of topoisomerase IV from these mutants, but not in the gyrA, gyrB, and parE gene coding for the GyrA and GyrB subunits of DNA gyrase and the ParE subunit of topoisomerase IV. Similarly, such an alteration in QRDR of parC was found in the field isolates of M. bovirhinis, which possessed various levels of QR. The substitution of leucine (Leu) by serine (Ser) at position 80 of QRDR of ParC was observed in both QR-mutants and QR-isolates. This is the first report of QR based on a point mutation of the parC gene in M. bovirhinis.  相似文献   

3.
取临床分离的、对5种氟喹诺酮类药物（环丙沙星、氧氟沙星、恩诺沙星、单诺沙星和沙拉沙星）均耐药的9株鸡源性沙门氏菌耐药株,提取其染色体DNA。设计引物gyrAF和gyrAR、gyrBF和gyrBR,分别扩增菌株DNA旋转酶gyrA基因和gyrB基因的氟喹诺酮类耐药决定区（QRDR）,对PCR扩增产物进行测序及序列分析。与质控菌株相比,9株临床分离耐药株中只有菌株38和60的gyrA基因发生单碱基突变,菌株38的gyrA基因第371位碱基发生C→T突变,菌株60的gyrA基因第350位碱基发生A→C突变,两处突变均位于QRDR内,其余菌株的核苷酸未发生任何突变。菌株38的碱基突变导致gyrA基因第99位氨基酸发生R→C取代,即Arg→Cys;菌株60的碱基突变导致gyrA基因第92位氨基酸发生M→L取代,即Met→Leu。9株临床分离鸡源性沙门氏菌氟喹诺酮类耐药株gyrB基因QRDR的核苷酸序列与质控菌株完全相同;只有菌株42的gyrB基因第1592位碱基发生C→A突变,但其位于gyrB基因QRDR之外,且菌株42的gyrB基因的碱基突变并没有导致相应氨基酸的改变。上述结果提示,DNA旋转酶gyrA基因和gyrB基因QRDR突变可能并非沙门氏菌耐药性产生的主要原因。  相似文献   

4.
选择11株动物源沙门菌(包括6种血清型)进行环丙沙星耐药性体外诱导.应用变性高效液相色谱(DH-PLC)对11株诱导株不同诱导阶段的靶基因gyrA、gyrB、parC、parE的喹诺酮耐药决定区(QRDR)和mar操纵子基因marO、marR、marA、marB、soxR、soxS及外排泵acrAB的抑制基因acrR(包括启动子区)进行基因突变筛选,并对筛选出的突变基因进行测序确证.结果显示,6种血清型沙门菌在诱导过程中,GyrA突变集中在S83F和/或D87G,marR、soxR、acrR均出现新突变,提示在环丙沙星诱导压力下,因靶基因和调控基因突变使耐药性不断增加.  相似文献   

5.
Nine quinolone resistant (minimal inhibitory concentration [MIC] was > 32 microg/mL for nalidixic acid, > 1 microg/mL for ciprofloxacin) isolates of Escherichia coli have been found in wild birds with septicemia. All of the isolates were aerobactin positive. The mechanisms of resistance were characterised by sequencing the quinolone resistance-determining region (QRDR) of the gyrA, gyrB, parC, and parE genes. Sequence analysis of the gyrA gene in all isolates identified only 1 nucleotide substitution at codon Serine-83 for Leucine-83. Sequence analysis of the gyrB, parC, and parE QRDR genes revealed no mutations in any of the isolates. This study was conducted to determine the importance of these genes in the susceptibility of E. coli strains isolated from wild birds to quinolones.  相似文献   

6.
通过药敏实验检测了鸡鲍氏、人鲍氏和人福氏三株志贺菌对12种常用抗生素的耐药情况,发现三者均未产生对喹诺酮类药物的耐药性。用聚合酶链反应(PCR)分别扩增三株志贺菌的DNA旋转酶A亚单位(gyrA)和拓扑异构酶ⅣC亚单位(parC)基因,并对其中的耐喹诺酮类决定区(QRDR)进行了分析。发现鸡和人鲍氏志贺菌QRDR区的序列没有发生任何碱基突变,这与药敏试验结果相吻合。人福氏志贺菌虽然也对喹诺酮类无耐药性,但其gyrA基因存在83位Ser83(TCG)→Leu(TTG)的突变,由于只有83位点一处突变,所以尚未表现出耐药性表征,parC基因中存在58位Ser58(AGC)→Ile(ATC)的突变,该突变点与常见的80、84位氯基酸的改变有所不同,却仍在QRDR区域之中,虽然暂时还无法根据这一结果判断该突变与喹诺酮类耐药性之间的关系,但至少表明该菌株正处在耐药性演变进程之中,其在志贺菌耐药性中的确切作用还有待进一步研究。  相似文献   

7.
为了探讨耐喹诺酮类决定区(QRDR)、外排泵负调控基因(acrR、marR和soxR)突变对临床分离株氟喹诺酮(FQs)高水平耐药的影响,本研究对临床分离的18株FQs耐药大肠杆菌(E.coli),采用PCR方法检测QRDR、acrR、marR和soxR的突变情况;通过RT-PCR的方法检测外排泵及膜孔蛋白相关基因的表达水平。结果显示,QRDR的突变主要集中在常规突变GyrA(Ser83Leu 和 Asp87Asn)和ParC(Ser80Ile),同时也检测出稀有突变ParC Glu84Gly、Glu84Lys、Glu84Val和Glu84Ala,ParE Ser458Ala等。ED28在acrR基因存在777 bp插入序列;12株菌(包括ATCC25922)在MarR存在Gly103Ser和Tyr137His双突变,其中EP26和EG42存在插入片段;ED40在SoxR存在Thr38Ser、Gly74Arg氨基酸替换。在多突变药菌株中,AcrAB的表达水平明显升高,OmpC和OmpF表达量降低、甚至缺失。  相似文献   

8.
The genetic diversity of 115 Campylobacter coli strains, isolated from pigs of 59 geographical distant farms in Switzerland, were characterized on the basis of their DNA fingerprints and resistance to macrolides and fluoroquinolones. Sequence analysis showed that the macrolide-resistant isolates had a point mutation in the 23S ribosomal RNA (rRNA) genes (A2075G) and that the fluoroquinolone-resistant isolates had a point mutation in the gyrase gene gyrA (C257T). One fluoroquinolone-resistant strain had an additional transition mutation in the gyrB gene (A1471C). The flaA restriction fragment length polymorphism (RFLP) genotyping revealed that 57% of the isolates were genetically different. Point mutations in the 23S rRNA and gyrA genes could be found in both genetically distant and genetically related isolates. Additionally, isolates with and without point mutations were found within individual farms and on different farms. This study showed that the ciprofloxacin and erythromycin-resistant C. coli population present on the pig farms is not issued from a common ancestral clone, but individual Campylobacter strains have most likely mutated independently to acquire resistances under the selective pressure of an antibiotic.  相似文献   

9.
The prevalence of qnr genes was investigated in veterinary clinical isolates of Escherichia coli in Guangdong province, China, and the aac (6')-Ib gene and the mutations in QRDRs of gyrase and topoisomerase IV were examined in qnr-positive strains. A total of 232 E. coli strains isolated from pig and poultry were screened for the presence of the qnrA, qnrB and qnrS genes by PCR and sequencing. The aac (6')-Ib gene was detected in qnr-bearing strains by PCR and sequencing. For all strains carrying qnr, MICs for six quinolones were determined. Mutations within the gyrase and topoisomerase were analyzed by PCR and sequencing for all the QRDRs of gyrA, gyrB, parC and parE. Among 232 E. coli isolates, 14 (6%) isolates were positive for the qnr gene, including one for qnrB, 13 for qnrS, but no qnrA was identified in this population. Detection of the aac (6')-Ib gene showed that one qnrS-positive isolate from pig and one qnrB-positive isolate from duck carried aac (6')-Ib gene, and both were the cr variant allele of aac (6')-Ib. All of the 14 isolates had MICs of ciprofloxacin more than 0.25 mg/L. Mutations in the QRDR of gyrA mutations were observed in 5 (35.7%) of the 14 strains. Three fluoroquinolone-resisting strains showed one mutation S83L of gyrA, while one S83I. One high-level resistance strains harboured gyrA S83L and A87N of gyrA. A singe mutation in site 58 of parC was detected in 3 (21.4%) strains. None mutations were found in QRDRs of gyrB and parE. The emergence of qnr genes in veterinary clinical E. coli isolates is described for the first time. This is also the first report of aac (6')-Ib-cr gene in E. coli isolates from food-producing animals.  相似文献   

10.
本研究旨在探讨不同血清型沙门氏菌在环丙沙星抗生素压力下突变频率及在耐药发展过程中靶位基因突变、外排泵及调控基因表达的差异。选取临床分离的印第安纳型、肠炎型和鼠伤寒型沙门氏菌的敏感菌株,在环丙沙星压力下诱导耐药突变,分别获得一系列不同程度的耐药突变株。分别检测不同血清型沙门氏菌突变株的突变频率、靶位基因喹诺酮耐药决定区(QRDRs)和外排泵调控基因ramR-ramA突变及外排泵相关基因的表达水平;同时检测了母株在羰基氰化物间氯苯腙(CCCP)存在情况下环丙沙星药物的蓄积浓度,以确定母株是否存在外排泵的作用。结果表明,在环丙沙星压力下,印第安纳型沙门氏菌较肠炎型和鼠伤寒型有更高的突变频率,易获得耐药株;印第安纳血清型菌株耐药性的获得主要是由于靶位基因gyrA发生单突变,协同外排泵外排作用增强而获得高水平耐药;肠炎型沙门氏菌耐药性获得主要是由于靶位基因gyrA发生83和87位双位点突变,并随着gyrB和parC基因的多位点同时突变而获得高水平耐药,耐药性的发展过程中没有外排泵作用参与;而鼠伤寒沙门氏菌在抗生素压力下不易发展成耐药菌,耐药性发生主要是由于靶位基因gyrB发生突变,而伴随parC基因突变及微弱的外排泵作用导致耐药水平增加。  相似文献   

11.
OBJECTIVE: To investigate the development of enrofloxacin resistance among Escherichia coli isolates obtained from chickens by determining mutant-prevention concentrations (MPCs) and sequence the quinolone resistance-determining regions (QRDRs) of gyrA and parC genes in selected isolates. SAMPLE POPULATION: 15 chicken-derived E coli isolates. PROCEDURES: For all isolates, MPC and minimal inhibition concentration (MIC) of enrofloxacin were determined. The MPCs and maximum serum drug concentrations attained with enrofloxacin doses recommended for treatment of E coli infections in chickens were compared. Mutation frequencies and QRDR sequence changes in gyrA and parC were also determined. RESULTS: In 2 of 15 E coli strains, MPCs were low (0.016 and 0.062 microg/mL), MPC:MIC ratios were 2 and 4, and the GyrA and ParC proteins had no mutations. In 9 susceptible isolates with a GyrA point mutation, MPCs ranged from 2 to 16 microg/mL. For isolates with double mutations in GyrA and a single mutation in ParC, MPCs were > 32 microg/mL (several fold greater than the maximal plasma concentration of enrofloxacin in chickens); mutation frequencies were also much lower, compared with frequencies for single-mutation isolates. CONCLUSIONS AND CLINICAL RELEVANCE: For E coli infections of chickens, MPC appears to be useful for determining enrofloxacin-dosing strategies. The high MPC:MIC ratio may result in enrofloxacin-treatment failure in chickens infected with some wild-type gyrA E coli isolates despite the isolates' enrofloxacin susceptibility (MICs 0.125 to 1 microg/mL). For infections involving isolates with high MPCs, especially those containing mutations in gyrA and parC genes, treatment with combinations of antimicrobials should be adopted.  相似文献   

12.
沙门氏菌耐药株gyrA基因和parC基因突变特征分析   总被引：3，自引：0，他引：3  
提取沙门氏菌染色体DNA，设计引物扩增gyrA基因和parC基因片段，克隆测序寻找耐药菌株的突变位点，通过系统的比较，分析氟喹诺酮类药物（以环丙沙星为代表）对各沙门氏菌MIC和耐药突变位点之间的关系。通过对耐药突变位点的研究，可以为下一步研究耐药性监测的快速方法提供理论基础。  相似文献   

13.
探讨不同禽源大肠埃希菌中喹诺酮类药物的耐药情况及耐药基因gyrA的分布和突变特征。采用K-B药敏纸片法、gyrA基因的PCR扩增,对9株大肠埃希菌进行喹诺酮类药物试验,并将gyrA基因的PCR产物测序,对测序结果采用DNA MAN、DNA Star、MEGA6等软件分析。药敏试验结果表明,C1、C2、C3菌株对左氧沙星、氧氟沙星、环丙沙星、诺氟沙星敏感,D1、D2、D3、B1、B2和B3菌株对左氧沙星、氧氟沙星、环丙沙星、诺氟沙星均表现为耐药和中介;gyrA基因的测序结果表明,除B1菌株有1处核苷酸突变位点和B2菌株有14处核苷酸突变位点;B2菌株gyrA基因的氨基酸突变发生在87位Ile→Val替代、101位Leu→Met替代、102位Ala→Ser替代、129位Lys→Gln替代。9株禽源大肠埃希菌的同源性和进化树分析表明,不同禽源耐氟喹诺酮类药物的大肠埃希菌菌株中B2菌株gyrA基因与其他9株菌株相比,同源性在90%左右,进化树不在一个分支上,研究中的B2菌株将为大肠埃希菌的氟喹诺酮类耐药机制的研究提供候选菌株。  相似文献   

14.
The aim of this study was to determine antimicrobial resistance of Aeromonas hydrophila isolated from farmed Nile Tilapia. A total of 50 A. hydrophila isolates from clinical cases were screened for the presence of class 1, 2 and 3 integrons and all the strains resistant to enrofloxacin and/or ciprofloxacin (n=19) examined for mutation in the quinolone resistance-determining regions (QRDRs) of gyrA and parC. The intI1 gene was detected in 23 A. hydrophila strains (46%) but no intl2 and intl3 were detected. Among these, 14 isolates (60.8%) carried gene cassettes inserted in variable regions i.e., partial aadA2, aadA2, dfrA1-orfC and dfrA12-aadA2, of which the most common gene cassette array was dfrA12-aadA2 (26.09%). Conjugal transfer of class 1 integrons with resistance gene array was detected. All the A. hydrophila strains resistant to enrofloxacin and/or ciprofloxacin possessed mutations in the QRDRs of gyrA and parC. Only a Ser-83-Ile substitution was identified in GyrA and only a Ser-80-Ile amino change was found in ParC. The data confirms that A. hydrophila from farm-raised Nile Telapia serve as a reservoir for antimicrobial resistance determinants.  相似文献   

15.
鸡大肠杆菌O78对喹诺酮类药物高耐药株的分子鉴定   总被引：1，自引：0，他引：1  
就临床分离的鸡大肠杆菌O78对喹诺酮类药物的最低抑菌浓度（MIC）进行了测定，得到对喹诺酮类药物有不同耐药水平的细菌23株。根据GenBank已公布的QRDRs序列，设计了分剐扩增gyrA、gyrB、parC和parE基因的4对引物，以筛选的23株耐药菌DNA为模板，进行了PCR扩增。序列分析及AcrA的Western blotting检测结果表明，临床分离的鸡大肠杆菌对喹诺酮类药物的耐药水平与GyrA和ParC的突变密切相关，而AcrAB外输泵的表达水平无显著变化。提示临床分离的鸡大肠杆菌O78的耐药水平与喹诺酮类药物的选择性压力有关，它诱导了DNA旋转酶和拓扑异构酶IV的基因突变，可能不能激活AcrAB外输泵。  相似文献   

16.
采用二倍稀释法测定临床分离的4株鸡毒支原体对常用抗菌药物的敏感性,PCR方法和基因测序法对鸡毒支原体DNA回旋酶编码基因gyrA、gyrB及拓扑异构酶Ⅳ编码基因parC和parE耐药决定区进行分析。敏感性测定结果表明,4株分离鸡毒支原体对泰乐菌素、泰妙林、沃尼妙林和替米考星有很高的敏感性,对四环素和红霉素中度敏感,对林可霉素、氟苯尼考和氟喹诺酮类药物呈现不同程度的耐药性。4株耐氟喹诺酮类药物鸡毒支原体均在GyrA和ParC的喹诺酮类耐药决定区(QRDR)发生氨基酸的改变,GyrA的氨基酸取代模式有两种,分别为Ser81→Gly和Ser83→Ile,ParC仅在80位发生氨基酸取代(Ser80→Leu),GyrB和ParE均未发生氨基酸改变。  相似文献   

17.
建立人离体肠道模拟模型，研究微量环丙沙星对人源肠道大肠杆菌和粪肠球菌敏感性的影响，进而用聚合酶链反应法扩增耐药菌的gyrA基因的耐药决定区，并分析其耐药机制。结果显示，大肠杆菌连续培养后存活菌株对微量环丙沙星耐药，此耐药菌对其他抗菌药敏感；粪肠球菌绎连续培养，对环丙沙星和其他抗菌药物仍敏感；耐药大肠杆菌的gyrA基因发生突变，248位碱基由C变为T，259位由G变为T，相应地，该基因编码的蛋白质在83位的丝氨酸和87位的天冬氨酸分别改变为亮氨酸和酪氨酸。研究表明，微量环丙沙星对人肠道菌群具有不同的选择作用，能诱导大肠杆菌产生耐药性。这为动物源食品中环丙沙星残留的安全性评价提供了试验依据。  相似文献   

18.
The antibacterial activity, selection of Escherichia coli (E. coli) mutants and mechanisms of fluoroquinolone resistance were investigated by integrating the minimum inhibitory concentration (MIC), mutant prevention concentration (MPC) and in vitro dynamic model approaches. Difloxacin and orbifloxacin, for which the above information has been scarce, were used. A range of area under curve over a 24h interval (AUC(24h))/MIC ratios and selected E. coli strains were investigated using the dynamic models. Continuous incubation for three days in the presence of difloxacin or orbifloxacin resulted in losses in E. coli susceptibility. An AUC(24h)/MIC (AUC(24h)/MPC)-dependent fluoroquinolone activity and selection of E. coli mutants was confirmed. Maximum losses in susceptibility occurred at AUC(24h)/MIC ratios of 54 (orbifloxacin) and 57.3 (difloxacin). AUC(24h)/MIC ratios of 169.8 (orbifloxacin) and 199.5 (difloxacin) were estimated to be protective against the selection of E. coli mutants, and the corresponding ratios based on AUC(24h)/MPC predictions were 34 (orbifloxacin) and 36.3 (difloxacin). When integrating our in vitro data with pharmacokinetic data in dogs, the conventional clinical doses of both drugs were found to be inadequate to attain the above protective values for 90% of the mutant subpopulation (AUC(24h)/MPC(90)). Both target mutations, esp. at codon 83 (Ser to Leu) of gyrA, and overexpression of efflux pumps contributed to resistance development, with mutants also showing decreased susceptibility to enrofloxacin and marbofloxacin. Additional studies would determine the role of mutations found outside the QRDR, at codon 24 of gyrA, and at codon 116 of parC, and establish the significance of these observations in vivo.  相似文献   

19.
本试验旨在了解毛皮动物源大肠杆菌的耐药性,有效控制毛皮动物细菌病的发生.针对14株分离自毛皮动物的大肠杆菌,采用PCR方法检测氟喹诺酮类耐药基因gyrA的携带情况,并对扩增得到的gyrA基因进行克隆测序和同源性分析;进一步针对gyrA基因制备地高辛标记的核酸探针,使用斑点杂交检测大肠杆菌对氟喹诺酮类药物的耐药情况;使用牛津杯法检测了大肠杆菌分离株对复方中药的敏感性.结果显示,PCR检出gyrA基因的阳性携带率为57.1%,斑点杂交检出耐氟喹诺酮类大肠杆菌的阳性率为50.0%,对复方中药的耐药率为28.6%.结果表明,毛皮动物对氟喹诺酮类药物的耐药性非常严重,对中药表现较高的敏感性,研究结果将为临床毛皮动物大肠杆菌病的防制提供依据.  相似文献   

20.
The aim of this study was to investigate the resistance to fluoroquinolones and compound Chinese medicine, and control colibacillosis in fur-bearing animals.14 E.coli strains isolated from diseased fur-bearing animals were detected by PCR for the fluoroquinolone-resistant gyrA gene,and then the PCR fragment of gyrA gene was cloned,sequenced and analyzed for homology.Afterwards,the fragment was labeled with digoxigenin as DNA probe for dot-blot hybridization detection.The resistance to compound Chinese medicine was detected by Oxford-cup tests.The results demonstrated that the positive rates of PCR and dot-blot hybridization were 57.1% and 50.0%,respectively.Only 28.6% of the E.coli strains were resistant to compound Chinese medicine.The results indicated that the resistance to fluoroquinolones in E.coli strains from fur-bearing animals was severe,however,the isolates were much more sensitive to compound Chinese medicine.The results would provide basis for control of colibacillosis of fur-bearing animals.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号